Free Trial

Karyopharm Therapeutics Q3 2024 Earnings Report

Karyopharm Therapeutics logo
$3.54 -0.20 (-5.35%)
As of 04:00 PM Eastern

Karyopharm Therapeutics EPS Results

Actual EPS
-$3.90
Consensus EPS
-$4.05
Beat/Miss
Beat by +$0.15
One Year Ago EPS
-$4.50

Karyopharm Therapeutics Revenue Results

Actual Revenue
$38.78 million
Expected Revenue
$37.86 million
Beat/Miss
Beat by +$920.00 thousand
YoY Revenue Growth
N/A

Karyopharm Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Remove Ads

Karyopharm Therapeutics Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler
Karyopharm price target lowered to $54 from $75 at Baird
See More Karyopharm Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Karyopharm Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Karyopharm Therapeutics and other key companies, straight to your email.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ:KPTI), a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

View Karyopharm Therapeutics Profile

More Earnings Resources from MarketBeat